It ameliorates muscle atrophy in cachexia or denervation via activating mTOR signaling pathway or reducing expression of atrogenes, such as MuRF1 and Atrogin-1 (Chen et al., 2016; Wu et al., 2019). The gene discussed is FBXO32; the disease is Cachexia.